ArticleObstetrics & gynecology science2026
A substantial proportion of patients with recurrent implantation failure treated with partner lymphocyte immunotherapy achieved live birth within 3 years after immunization.
Article in Obstetrics & gynecology science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveIn the 1980s, the immunotolerance-inducing effect of leukocytes in blood products was observed and our department started using partner lymphocyte immunotherapy (LIT) for patients experiencing recurrent miscarriage. We also used LIT for couples with unexplained infertility who had undergone at least three unsuccessful embryo transfers. The aim of this study was to analyze the live birth rate after LIT in our patient cohort with recurrent implantation failure.
methodsFrom 2017 to 2022, we conducted a prospective, noninterventional, observational study of patients who received a questionnaire two to 3 years after LIT. We also performed T- and B-cell crossmatches, human leukocyte antigen (HLA) typing, and complement-dependent cytotoxicity assays.
resultsWe sent questionnaires to 475 couples with unexplained infertility and received 268 responses. A total of 157 live births (58.6%) within 3 years of LIT were reported. We identified a higher proportion of HLA-crossmatch-positive cases in the live birth group (71.8%) than in the group without live births (59.5%). The median age was 34 years in the live birth group and 36 years in the group without live births. We observed no significant influence of additional therapies including immunoglobulins, corticosteroids, anticoagulants, granulocyte colony-stimulating factor, or lipid infusions.
conclusionIn our patient cohort, we observed an substantial proportion of patients giving live birth within 3 years after LIT. An individual treatment decision is required for each patient, as the efficacy of LIT in patients with unexplained infertility needs to be proven in a controlled, randomized study in the future.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.